Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Recruiting 5Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma, Mantle-Cell 1Lymphoma 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 275pembrolizumab 267Carboplatin 190Cyclophosphamide 185Biopsy 178Cisplatin 164Gemcitabine 139Paclitaxel 137Bevacizumab 123fludarabine 122Nivolumab 117Radiotherapy 113Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 88Capecitabine 88Dexamethasone 85Drug Therapy 76Pemetrexed 75Rituximab 73durvalumab 71Leucovorin 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 67atezolizumab 64Doxorubicin 64Radiation 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × loncastuximab tesirine × 90 days × Clear all
NCT05464719 2026-05-20

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma

NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05672251 2026-05-11

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04998669 2026-03-23

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

University of Miami

Phase 2 Recruiting
100 enrolled
Lymphoid

Lymphoma, Follicular

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡